대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Effect of SGLT2 Inhibitors on Anemia and Inflammation In CKD
저자	Sherzod Abdullaev
출판정보	2024; 2024(1):
키워드
초록	Objectives: SGLT2 inhibitors (SGLT2i) were reported to increase hemoglobin (Hb) by suppressing hepcidin and increasing erythropoietin, similar to hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors. We analyzed the increasing of Hb by SGLT2i might be more prominent among patients with inflammation in CKD. Methods: In this retrospective cohort study, diabetic patients from 2020 to 2022 at single center were enrolled. The Hb slope within 8 months after initiation of SGLT2i (the first 6 months of the observation period for non-users) was analyzed using a mixed-effects model. Non-linear regression models were fitted with restricted cubic splines to investigate Hb levels at the last visit across different eGFR levels. Analyses were performed separately for those with higher and lower than the median baseline C-reactive protein (CRP) levels. The data were adjusted for potential confounders. Results: Among 175 patients, 43 were on SGLT2i (Dapagliflozin 10 mg daily). During the first 8 months, CRP and eGFR trajectories were not significantly different between users and non-users of SGLT2i. Differences in Hb slope between users and non-users of SGLT2i were 0.18 (0.06–0.22) and 0.04 (-0.05–0.12) g/dL/month for those with higher and lower baseline CRP, respectively. Hb levels at the last visit were significantly higher among SGLT2i users across the range of eGFR levels, and it was more prominent among those with higher CRP (p<0.1). Conclusions: SGLT2i use was associated with higher Hb levels, especially among those with inflammation across the range of eGFR levels. The results suggest that SGLT2i could improve anemia among patients with anemia of chronic kidney disease and inflammation which are refractory to treatment with erythropoiesis-stimulating agents. Further studies are needed to enhance our understanding of mechanism of action and to optimize patients’ management.
원문(PDF)	PDF 원문보기

목록

위로가기